Duquesne Family Office’s Nektar Therapeutics NKTR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-66,667
| Closed | -$18M | – | 57 |
|
|
2021
Q3 | $18M | Hold |
66,667
| – | – | 0.58% | 31 |
|
|
2021
Q2 | $17.2M | Hold |
66,667
| – | – | 0.43% | 39 |
|
|
2021
Q1 | $20M | Buy |
+66,667
| New | +$20M | 0.44% | 48 |
|
|
2020
Q1 | – | Sell |
-20,705
| Closed | -$6.7M | – | 56 |
|
|
2019
Q4 | $6.7M | Buy |
+20,705
| New | +$6.7M | 0.2% | 47 |
|
|
2018
Q2 | – | Sell |
-79,487
| Closed | -$127M | – | 37 |
|
|
2018
Q1 | $127M | Sell |
79,487
-42,780
| -35% | -$68.2M | 7% | 6 |
|
|
2017
Q4 | $110M | Buy |
122,267
+44,527
| +57% | +$39.9M | 5.52% | 6 |
|
|
2017
Q3 | $28M | Hold |
77,740
| – | – | 1.27% | 19 |
|
|
2017
Q2 | $22.8M | Buy |
77,740
+33,367
| +75% | +$9.78M | 1.22% | 25 |
|
|
2017
Q1 | $15.6M | Buy |
+44,373
| New | +$15.6M | 1.02% | 30 |
|
|
2016
Q4 | – | Sell |
-38,140
| Closed | -$9.83M | – | 53 |
|
|
2016
Q3 | $9.83M | Buy |
+38,140
| New | +$9.83M | 0.87% | 38 |
|
|
2015
Q2 | – | Sell |
-43,667
| Closed | -$7.21M | – | 39 |
|
|
2015
Q1 | $7.21M | Hold |
43,667
| – | – | 0.92% | 23 |
|
|
2014
Q4 | $10.2M | Buy |
+43,667
| New | +$10.2M | 1% | 31 |
|